A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer

Xin Shuai Wang, De Jiu Kong, Tzu-Yin Lin, Xiao Cen Li, Yoshihiro Izumiya, Xue Zhen Ding, Li Zhang, Xiao Chen Hu, Jun Qiang Yang, She Gan Gao, Kit Lam, Yuanpei Li

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

One of the major goals of precision oncology is to promote combination therapy to improve efficacy and reduce side effects of anti-cancer drugs based on their molecular mechanisms. In this study, we aimed to develop and validate new nanoformulations of docetaxel (DTX) and bortezomib (BTZ) for targeted combination therapy to treat human esophageal cancer. By leveraging our versatile disulfide cross-linked micelles (DCMs) platform, we developed nanoformulations of DTX and BTZ (named DTX-DCMs and BTZ-DCMs). Their physical properties were characterized; their anti-cancer efficacies and mechanisms of action were investigated in a human esophageal cancer cell line in vitro. Furthermore, the in vitro anti-tumor activities of combination therapies (concurrent drug treatment, sequential drug treatment, and treatment using different ratios of the drugs) were examined in comparison with the single drug treatment and free drug strategies. These drug-loaded nanoparticles were spherical in shape and relatively small in size of approximately 20-22 nm. The entrapment efficiencies of DTX and BTZ into nanoparticles were 82.4% and 84.1%, respectively. The drug release rates of DTX-DCMs and BTZ-DCMs were sustained, and greatly increased in the presence of GSH. These nanodrugs were effectively internalized by KYSE30 esophageal cancer cells, and dose-dependently induced cell apoptosis. We further revealed a strong synergistic effect between DTX-DCMs and BTZ-DCMs against KYSE30 esophageal cancer cells. Sequential combination therapy with DTX-DCMs followed by BTZ-DCMs exhibited the best anti-tumor efficacy in vitro. This study demonstrates that DTX and BTZ could be successfully nanoformulated into disulfide cross-linked micelles. The nanoformulations of DTX and BTZ demonstrate an immense potential for synergistic combination therapy to treat human esophageal cancer.

Original languageEnglish (US)
Pages (from-to)931-942
Number of pages12
JournalActa Pharmacologica Sinica
Volume38
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

docetaxel
Micelles
Esophageal Neoplasms
Disulfides
Pharmaceutical Preparations
Therapeutics
Nanoparticles
Neoplasms
Bortezomib
Combination Drug Therapy

Keywords

  • Bortezomib
  • Disulfide cross-linked micelles
  • Docetaxel
  • Human esophageal cancer
  • Nanoformulations
  • Synergistic effect
  • Targeted combination therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer. / Wang, Xin Shuai; Kong, De Jiu; Lin, Tzu-Yin; Li, Xiao Cen; Izumiya, Yoshihiro; Ding, Xue Zhen; Zhang, Li; Hu, Xiao Chen; Yang, Jun Qiang; Gao, She Gan; Lam, Kit; Li, Yuanpei.

In: Acta Pharmacologica Sinica, Vol. 38, No. 6, 01.06.2017, p. 931-942.

Research output: Contribution to journalArticle

Wang, Xin Shuai ; Kong, De Jiu ; Lin, Tzu-Yin ; Li, Xiao Cen ; Izumiya, Yoshihiro ; Ding, Xue Zhen ; Zhang, Li ; Hu, Xiao Chen ; Yang, Jun Qiang ; Gao, She Gan ; Lam, Kit ; Li, Yuanpei. / A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer. In: Acta Pharmacologica Sinica. 2017 ; Vol. 38, No. 6. pp. 931-942.
@article{77ac4e68cb7e4b519f5603df916edc91,
title = "A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer",
abstract = "One of the major goals of precision oncology is to promote combination therapy to improve efficacy and reduce side effects of anti-cancer drugs based on their molecular mechanisms. In this study, we aimed to develop and validate new nanoformulations of docetaxel (DTX) and bortezomib (BTZ) for targeted combination therapy to treat human esophageal cancer. By leveraging our versatile disulfide cross-linked micelles (DCMs) platform, we developed nanoformulations of DTX and BTZ (named DTX-DCMs and BTZ-DCMs). Their physical properties were characterized; their anti-cancer efficacies and mechanisms of action were investigated in a human esophageal cancer cell line in vitro. Furthermore, the in vitro anti-tumor activities of combination therapies (concurrent drug treatment, sequential drug treatment, and treatment using different ratios of the drugs) were examined in comparison with the single drug treatment and free drug strategies. These drug-loaded nanoparticles were spherical in shape and relatively small in size of approximately 20-22 nm. The entrapment efficiencies of DTX and BTZ into nanoparticles were 82.4{\%} and 84.1{\%}, respectively. The drug release rates of DTX-DCMs and BTZ-DCMs were sustained, and greatly increased in the presence of GSH. These nanodrugs were effectively internalized by KYSE30 esophageal cancer cells, and dose-dependently induced cell apoptosis. We further revealed a strong synergistic effect between DTX-DCMs and BTZ-DCMs against KYSE30 esophageal cancer cells. Sequential combination therapy with DTX-DCMs followed by BTZ-DCMs exhibited the best anti-tumor efficacy in vitro. This study demonstrates that DTX and BTZ could be successfully nanoformulated into disulfide cross-linked micelles. The nanoformulations of DTX and BTZ demonstrate an immense potential for synergistic combination therapy to treat human esophageal cancer.",
keywords = "Bortezomib, Disulfide cross-linked micelles, Docetaxel, Human esophageal cancer, Nanoformulations, Synergistic effect, Targeted combination therapy",
author = "Wang, {Xin Shuai} and Kong, {De Jiu} and Tzu-Yin Lin and Li, {Xiao Cen} and Yoshihiro Izumiya and Ding, {Xue Zhen} and Li Zhang and Hu, {Xiao Chen} and Yang, {Jun Qiang} and Gao, {She Gan} and Kit Lam and Yuanpei Li",
year = "2017",
month = "6",
day = "1",
doi = "10.1038/aps.2017.43",
language = "English (US)",
volume = "38",
pages = "931--942",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer

AU - Wang, Xin Shuai

AU - Kong, De Jiu

AU - Lin, Tzu-Yin

AU - Li, Xiao Cen

AU - Izumiya, Yoshihiro

AU - Ding, Xue Zhen

AU - Zhang, Li

AU - Hu, Xiao Chen

AU - Yang, Jun Qiang

AU - Gao, She Gan

AU - Lam, Kit

AU - Li, Yuanpei

PY - 2017/6/1

Y1 - 2017/6/1

N2 - One of the major goals of precision oncology is to promote combination therapy to improve efficacy and reduce side effects of anti-cancer drugs based on their molecular mechanisms. In this study, we aimed to develop and validate new nanoformulations of docetaxel (DTX) and bortezomib (BTZ) for targeted combination therapy to treat human esophageal cancer. By leveraging our versatile disulfide cross-linked micelles (DCMs) platform, we developed nanoformulations of DTX and BTZ (named DTX-DCMs and BTZ-DCMs). Their physical properties were characterized; their anti-cancer efficacies and mechanisms of action were investigated in a human esophageal cancer cell line in vitro. Furthermore, the in vitro anti-tumor activities of combination therapies (concurrent drug treatment, sequential drug treatment, and treatment using different ratios of the drugs) were examined in comparison with the single drug treatment and free drug strategies. These drug-loaded nanoparticles were spherical in shape and relatively small in size of approximately 20-22 nm. The entrapment efficiencies of DTX and BTZ into nanoparticles were 82.4% and 84.1%, respectively. The drug release rates of DTX-DCMs and BTZ-DCMs were sustained, and greatly increased in the presence of GSH. These nanodrugs were effectively internalized by KYSE30 esophageal cancer cells, and dose-dependently induced cell apoptosis. We further revealed a strong synergistic effect between DTX-DCMs and BTZ-DCMs against KYSE30 esophageal cancer cells. Sequential combination therapy with DTX-DCMs followed by BTZ-DCMs exhibited the best anti-tumor efficacy in vitro. This study demonstrates that DTX and BTZ could be successfully nanoformulated into disulfide cross-linked micelles. The nanoformulations of DTX and BTZ demonstrate an immense potential for synergistic combination therapy to treat human esophageal cancer.

AB - One of the major goals of precision oncology is to promote combination therapy to improve efficacy and reduce side effects of anti-cancer drugs based on their molecular mechanisms. In this study, we aimed to develop and validate new nanoformulations of docetaxel (DTX) and bortezomib (BTZ) for targeted combination therapy to treat human esophageal cancer. By leveraging our versatile disulfide cross-linked micelles (DCMs) platform, we developed nanoformulations of DTX and BTZ (named DTX-DCMs and BTZ-DCMs). Their physical properties were characterized; their anti-cancer efficacies and mechanisms of action were investigated in a human esophageal cancer cell line in vitro. Furthermore, the in vitro anti-tumor activities of combination therapies (concurrent drug treatment, sequential drug treatment, and treatment using different ratios of the drugs) were examined in comparison with the single drug treatment and free drug strategies. These drug-loaded nanoparticles were spherical in shape and relatively small in size of approximately 20-22 nm. The entrapment efficiencies of DTX and BTZ into nanoparticles were 82.4% and 84.1%, respectively. The drug release rates of DTX-DCMs and BTZ-DCMs were sustained, and greatly increased in the presence of GSH. These nanodrugs were effectively internalized by KYSE30 esophageal cancer cells, and dose-dependently induced cell apoptosis. We further revealed a strong synergistic effect between DTX-DCMs and BTZ-DCMs against KYSE30 esophageal cancer cells. Sequential combination therapy with DTX-DCMs followed by BTZ-DCMs exhibited the best anti-tumor efficacy in vitro. This study demonstrates that DTX and BTZ could be successfully nanoformulated into disulfide cross-linked micelles. The nanoformulations of DTX and BTZ demonstrate an immense potential for synergistic combination therapy to treat human esophageal cancer.

KW - Bortezomib

KW - Disulfide cross-linked micelles

KW - Docetaxel

KW - Human esophageal cancer

KW - Nanoformulations

KW - Synergistic effect

KW - Targeted combination therapy

UR - http://www.scopus.com/inward/record.url?scp=85020161705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020161705&partnerID=8YFLogxK

U2 - 10.1038/aps.2017.43

DO - 10.1038/aps.2017.43

M3 - Article

VL - 38

SP - 931

EP - 942

JO - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

IS - 6

ER -